Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma

Molecular Cancer Therapeutics

Volumn 8, Issue 8, 2009, Pages 2392-2401

  Huebener, Nicole ^a   Fest, Stefan ^b   Hilt, Kerstin ^a   Schramm, Alexander ^c   Eggert, Angelika ^c   Durmus, Tahir ^a   Woehler, Anja ^a   Stermann, Alexander ^a   Bleeke, Matthias ^a   Baykan, Bianca ^a   Weixler, Silke ^a   Gaedicke, Gerhard ^a   Lode, Holger N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CHO CELL; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; INTERFERON PRODUCTION; METASTASIS INHIBITION; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALMONELLA TYPHIMURIUM; TUMOR XENOGRAFT; VACCINE PRODUCTION;

ANIMALS; ANTIGENS, HETEROPHILE; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HUMANS; IMMUNIZATION; INTERLEUKIN-12; MICE; NEUROBLASTOMA; TYROSINE 3-MONOOXYGENASE; VACCINES, DNA;

EID: 68849122746     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0107     Document Type: Article

References (49)

1. Pritchard J, Cotterill SJ, Germond SM, et al. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) bythe European Neuroblastoma Study Group. Pediatr Blood Cancer 2005;44:348-57.
2. Volchenboum SL, Cohn SL. Progress in defining and treating high-risk neuroblastoma: lessons from the bench and bedside. J Clin Oncol 2009;27:1003-4.
3. Murphy C, Nikodem D, Howcroft K, Weissman JD, Singer DS. Active repression of major histocompatibility complex class I genes in a human neuroblastoma cell line. J Biol Chem 1996;271:30992-9.
4. Raffaghello L, Prigione I, Bocca P, et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 2005;24:4634-44.
5. Song L, Ara T, Wu HW, et al. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J Clin Invest 2007;117:2702-12.
6. Drew PD, Lonergan M, Goldstein ME, et al. Regulation of MHC class I and β 2-microglobulin gene expression in human neuronal cells. Factor binding to conserved cis-acting regulatory sequences correlates with expression of the genes. J Immunol 1993;150:3300-10.
7. Morandi F, Chiesa S, Bocca P, et al. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia 2006;8:833-42.
8. Gregor PD, Wolchok JD, Turaga V, et al. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 2005;116:415-21.
9. Marshall DJ, San Mateo LR, Rudnick KA, et al. Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine. Cancer Immunol Immunother 2005;54:1082-94.
10. Palomba ML, Roberts WK, Dao T, et al. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res 2005;11:370-9.
11. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
12. Loftus DJ, Castelli C, Clay TM, et al. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med 1996;184:647-57.
13. von Euw EM, Barrio MM, Furman D, et al. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10-1082 promoter genotype as predictor of disease progression. J Transl Med 2008;6:6-20.
14. Liu MA, Wahren B, Karlsson Hedestam GB. DNA vaccines: recent developments and future possibilities. Hum Gene Ther 2006;17:1051-61.
15. Tu CF, Lin CC, Chen MC, et al. Autologous neu DNA vaccine can be as effective as xenogenic neu DNA vaccine by altering administration route. Vaccine 2007;25:719-28.
16. Wang S, Zhang C, Zhang L, et al. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 2008;26:2100-10.
17. Yang S, Vervaert CE, Burch J, Jr., et al. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. Int J Cancer 1999;83:532-40.
18. Matzinger P. An innate sense of danger. Ann N Y Acad Sci 2002;961:341-2.
19. Huebener N, Lange B, Lemmel C, et al. Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma. Cancer Lett 2003;197:211-7.
20. Huebener N, Fest S, Strandsby A, et al. A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. Mol Cancer Ther 2008;7:2241-51.
21. Wolchok JD, Yuan J, Houghton AN, et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 2007;15:2044-50.
22. Weber LW, Bowne WB, Wolchok JD, et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998;102:1258-64.
23. Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998;188:1553-61.
24. Speiser DE, Baumgaertner P, Voelter V, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A 2008;105:3849-54.
25. Elzaouk L, Pavlovic J, Moelling K. Analysis of antitumor activity elicited by vaccination with combinations of interleukin-12 DNA with gp100 DNA or the chemokine CCL21 in vivo. Hum Gene Ther 2006;17:859-70.
26. Luo Y, Zhou H, Mizutani M, et al. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Cancer Res 2005;65:3419-27.
27. Zeng Y, Huebener N, Fest S, et al. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res 2007;67:2331-8.
28. Rodriguez F, Zhang J, Whitton JL. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 1997;71:8497-503.
29. Holzhutter HG, Frommel C, Kloetzel PM. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. J Mol Biol 1999;286:1251-65.
30. Lode HN, Dreier T, Xiang R, et al. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci U S A 1998;95:2475-80.
31. Lode HN, Xiang R, Varki NM, et al. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997;89:1586-94.
32. Lode HN, Xiang R, Dreier T, et al. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998;91:1706-15.
33. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
34. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-60.
35. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184-94.
36. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306.
37. Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006;24:4582-5.
38. Yamano T, Kaneda Y, Hiramatsu SH, et al. Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21. Cancer Gene Ther 2007;14:451-9.
39. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003;421:852-6.
40. Fest S, Huebener N, Bleeke M, et al. Survivin minigene DNA vaccination is effective against neuroblastoma. Int J Cancer 2009;125:104-14.
41. Goldberg SM, Bartido SM, Gardner JP, et al. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant αvirus replicon particles. Clin Cancer Res 2005;11:8114-21.
42. Orlandi F, Venanzi FM, Concetti A, et al. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clin Cancer Res 2007;13:6195-203.
43. Mescher MF, Curtsinger JM, Agarwal P, et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 2006;211:81-92.
44. Xu S, Koski GK, Faries M, et al. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003;171:2251-61.
45. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547-9.
46. Cochlovius B, Stassar MJ, Schreurs MW, Benner A, Adema GJ. Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity. Immunol Lett 2002;80:89-96.
47. Sabel MS, Arora A, Su G, et al. Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres. J Immunother 2007;30:808-16.
48. Zheng R, Cohen PA, Paustian CA, et al. Paired toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res 2008;68:4045-9.
49. Hueman MT, Stojadinovic A, Storrer CE, et al. Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother 2007;56:135-46.